Scarica l'app Stockscreener
4.24
0.47%
0.02
Precedente Chiudi:
$4.22
Aprire:
$4.25
Volume 24 ore:
25,981
Relative Volume:
0.33
Capitalizzazione di mercato:
$98.55M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-1.85%
1M Prestazione:
-26.26%
6M Prestazione:
-51.10%
1 anno Prestazione:
-46.93%
Intervallo 1D:
$4.04
$4.27
Intervallo di 1 settimana:
$4.04
$4.525
Portata 52W:
$4.04
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Nome
Actuate Therapeutics Inc
Settore
Industria
Telefono
847-986-4190
Indirizzo
1751 RIVER RUN, FORT WORTH
Compare ACTU vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
4.24 | 98.09M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-26 | Iniziato | B. Riley Securities | Buy |
| 2025-04-22 | Iniziato | Craig Hallum | Buy |
| 2025-03-17 | Iniziato | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Borsa (ACTU) Ultime notizie
Actuate Therapeutics (NASDAQ:ACTU) Shares Down 3.6%Here's What Happened - MarketBeat
What is the long term forecast for GATES GROUP Inc. stockJuly 2025 Selloffs & AI Enhanced Trading Signals - baoquankhu1.vn
Published on: 2026-02-07 16:03:44 - baoquankhu1.vn
Actuate Therapeutics registers 1.33M shares for resale by investors - MSN
Patterns Watch: Is Actuate Therapeutics Inc benefiting from innovation trendsJuly 2025 Sentiment & Risk Managed Investment Entry Signals - baoquankhu1.vn
Decliners Report: Is Actuate Therapeutics Inc benefiting from innovation trendsBreakout Watch & Daily Profit Maximizing Tips - baoquankhu1.vn
Becoming A Backbone Therapy: Lessons Learned With Actuate Therapeutics - Clinical Leader
Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap dropped US$13m last week; Private equity firms bore the brunt - Yahoo Finance
Sectors Review: Will Actuate Therapeutics Inc stock benefit from M AJuly 2025 Trade Ideas & Capital Efficiency Focused Strategies - baoquankhu1.vn
Actuate Therapeutics plans phase 1/2 trial of oral cancer drug - Investing.com Nigeria
Aug EndMonth: Whats the beta of PHGE stockJuly 2025 Chart Watch & Verified Entry Point Detection - baoquankhu1.vn
Actuate Therapeutics, Inc. Announces Initiation of Phase 1/2 Clinical Trial for Elraglusib Tablet in Advanced Cancers - Quiver Quantitative
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers - manilatimes.net
Actuate Therapeutics Announces Plans to Expand Clinical - GlobeNewswire
Actuate Therapeutics, Inc. (NASDAQ:ACTU) Sees Significant Growth in Short Interest - MarketBeat
Risk Report: Why is VNCE stock going down2025 Technical Patterns & Detailed Earnings Play Strategies - baoquankhu1.vn
Merger Talk: Is Actuate Therapeutics Inc stock undervalued right nowInflation Watch & Fast Moving Stock Trade Plans - baoquankhu1.vn
Actuate Therapeutics (NASDAQ:ACTU) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Actuate Therapeutics (NASDAQ:ACTU) Downgraded by Wall Street Zen to “Sell” - Defense World
Is Actuate Therapeutics Inc stock showing strong momentumPortfolio Return Report & Capital Protection Trade Alerts - baoquankhu1.vn
Actuate Therapeutics, Inc. (ACTU) Receives a Buy from Craig-Hallum - The Globe and Mail
Market Wrap: Does Actuate Therapeutics Inc have consistent dividend growth2025 Price Targets & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Published on: 2026-01-16 10:23:54 - baoquankhu1.vn
Published on: 2026-01-16 07:35:07 - baoquankhu1.vn
H.C. Wainwright reiterates Buy rating on Actuate Therapeutics stock at $20 - Investing.com UK
Price Action: Is Actuate Therapeutics Inc stock risky to hold nowPortfolio Gains Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Quarterly Recap: Can Actuate Therapeutics Inc stock deliver consistent earnings growthJuly 2025 WrapUp & Smart Money Movement Tracker - Bộ Nội Vụ
Actuate Therapeutics reports positive Phase 2 pancreatic cancer data - TipRanks
Actuate Therapeutics IncReports positive phase 2 trial data for elraglusibSEC filing - marketscreener.com
Actuate Therapeutics, Inc. Reports Positive Phase 2 Trial Results for Elraglusib - TradingView — Track All Markets
Actuate Therapeutics Reports Positive Phase 2 Study Results for Elraglusib Combination in Metastatic Pancreatic Cancer - Quiver Quantitative
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at AS - GlobeNewswire
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ... - Sahm
Todd Thomson Sells 280,000 Shares of Actuate Therapeutics (NASDAQ:ACTU) Stock - Defense World
Will Actuate Therapeutics Inc. stock benefit from green energy trendsJuly 2025 Trends & Long-Term Growth Stock Strategies - Улправда
Why Actuate Therapeutics Inc. stock is recommended by analysts2025 Pullback Review & Weekly Return Optimization Alerts - Улправда
Can Actuate Therapeutics Inc. stock sustain market leadershipJuly 2025 Final Week & Weekly Breakout Watchlists - Улправда
Insider at Actuate Therapeutics Makes a Major Move With Fresh Stock Sale - TipRanks
Actuate therapeutics director Kairos Venture Partners II, L.P. sells $1.6m in shares - Investing.com Nigeria
Actuate Therapeutics Insider Sold Shares Worth $1,624,000, According to a Recent SEC Filing - marketscreener.com
Actuate Therapeutics stock gets Buy rating after positive Phase 1 results - Investing.com Canada
Actuate Therapeutics stock gets Buy rating after positive Phase 1 results By Investing.com - Investing.com South Africa
Actuate Therapeutics stock rises on positive pediatric cancer trial data By Investing.com - Investing.com Nigeria
Actuate Therapeutics stock rises on positive pediatric cancer trial data - Investing.com
Actuate Therapeutics Reports Promising Initial Clinical Responses in Pediatric Cancers from Phase 1 Trial of Elraglusib - Quiver Quantitative
Experimental drug shrinks tough childhood tumors in early trial - Stock Titan
Analyst Downgrade: Is Actuate Therapeutics Inc stock supported by innovation pipelineTrade Performance Summary & Daily Profit Focused Stock Screening - moha.gov.vn
Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% Higher – Here’s What Happened - Defense World
Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% HigherHere's What Happened - MarketBeat
Can Actuate Therapeutics' Elraglusib Overcome The Hurdles Of GSK-3ß Inhibition? - RTTNews
Actuate Therapeutics Inc Azioni (ACTU) Dati Finanziari
Non sono disponibili dati finanziari per Actuate Therapeutics Inc (ACTU). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):